UB researchers have identified for the first time an enzyme in the foxglove plant that is responsible for the production of compounds needed to make the heart failure drug digoxin. The breakthrough ...

Oct. 30, 2002 — Digoxin may pose a risk of death for women with heart failure, according to a retrospective analysis published in the Oct. 31 issue of the New England Journal of Medicine. Yet ...

(HealthDay News) — Only 1 in 5 patients with heart failure with reduced ejection fraction (HFrEF) receive digoxin at discharge, according to a study published online in JACC: Heart Failure. Nish Patel ...

At present, digoxin should not be recommended for the treatment of patients with mild-to-moderate diastolic HF with preserved LVEF of greater than 45% in sinus rhythm This was an ancillary study ...

Findings from the current study demonstrate that over half of chronic HF patients in the DIG trial had severe and more advanced disease as evidenced by the presence of NYHA III–IV symptoms, LVEF <25%, ...

The Digitalis Investigation Group trial reported that treatment with digoxin did not decrease overall mortality among patients with heart failure and depressed left ventricular systolic function, ...

To the Editor: The report by Rathore et al. (Oct. 31 issue) 1 emphasizes differences according to sex in the outcomes of digoxin therapy in patients with congestive heart failure. Their post hoc ...

MADRID, Spain—Adding digitoxin, a cardiac glycoside, to contemporary guideline-directed medical therapy (GDMT) improves clinical outcomes in patients who have heart failure with reduced ejection ...

KAIMRC researchers have shown that a drug, commonly used to treat various types of heart failure, appears to increase mortality risk in certain groups of patients when it is used in place of current ...